Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Concord BiotechBOM:543960 -2.33%90 3-Year ROIIC % is 0.43 as of Mar. 2026, which is 97% below its 10-year median of 14.83. GuruFocus rates BOM:543960 with a GF Score™ of 90/100 and a GF Value™ of ₹1,693.45 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 1,312 Biotechnology companies, Concord Biotech ranks better than 53.28% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Concord Biotech's 3-Year ROIIC % for the quarter that ended in Mar. 2026 was 0.43%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Concord Biotech's 3-Year ROIIC % or its related term are showing as below:
BOM:543960's 3-Year ROIIC % is ranked better than 53.28% of 1312
companies
in the Biotechnology industry
Industry Median: -4.9
vs BOM:543960: 0.43
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Concord Biotech 3-Year ROIIC % Related Terms
Concord Biotech 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Concord Biotech's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:543960 vs VRTX, REGN, MRNA: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Concord Biotech's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Concord Biotech 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Concord Biotech's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Concord Biotech's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Concord Biotech (BOM:543960) has a 3-Year ROIIC % of 0.43 as of Mar. 2026. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Concord Biotech and its competitors. This is 97% below median its historical median of 14.83. Over the past decade, Concord Biotech's 3-Year ROIIC % has ranged from 0.43 to 35.74. According to the industry distribution chart, Concord Biotech ranks #613 out of 1312 companies in the Biotechnology industry, placing it in the top 46.7%.
Is Concord Biotech's 3-Year ROIIC % too high?
Concord Biotech's current 3-Year ROIIC % of 0.43 is 97% below median its 10-year median of 14.83. Over the past 10 years, this metric has ranged from a low of 0.43 to a high of 35.74. Based on the distribution chart, Concord Biotech ranks #613 out of 1312 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Concord Biotech has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Concord Biotech's 3-Year ROIIC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Concord Biotech ranks #613 out of 1312 companies for 3-Year ROIIC %. This puts Concord Biotech in the upper half of its industry. Historically, Concord Biotech's own 3-Year ROIIC % has ranged from 0.43 to 35.74 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Concord Biotech and its competitors. Concord Biotech's current 3-Year ROIIC % is 0.43, which is 97% below median its own 10-year median of 14.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Concord Biotech stock overvalued right now?
Based on GuruFocus' analysis, Concord Biotech (BOM:543960) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹1,693.45, compared to a current price of ₹1,414.75 — trading 16.5% below its estimated fair value. The current 3-Year ROIIC % is 0.43, which is 97% below median its 10-year median of 14.83. Concord Biotech's overall GF Score™ is 90/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Concord Biotech (BOM:543960), the current 3-Year ROIIC % is 0.43 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Concord Biotech (BOM:543960) Overvalued in 2026?
Based on GuruFocus' analysis, Concord Biotech stock appears to be undervalued.
The current stock price of ₹1,414.75 is trading 16.5% below its estimated GF Value™ of ₹1,693.45.
GuruFocus considers Concord Biotech to be Modestly Undervalued.
Key valuation signals for BOM:543960:
3-Year ROIIC %: 0.43 (97% below median its 10-year median of 14.83)
GF Value™: ₹1,693.45 vs. price of ₹1,414.75 (16.5% below fair value)
No single metric tells the full story. See the BOM:543960 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Concord Biotech Ltd is a research and development-driven biopharma company that manufactures Active Pharmaceutical Ingredients (API) through fermentation and semi-synthetic process and finished formulations. It is mainly engaged in the business of manufacturing and trading in pharmaceutical products. Geographically Company operates in two segments within India and outside India, having majority revenue from India.
90GF Score
Get the complete analysis for BOM:543960
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543960 has been successfully added to your 
